The Japanese Encephalitis drugs in development market research report provides comprehensive information on the therapeutics under development for Japanese Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Japanese Encephalitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Japanese Encephalitis by 12 companies/universities/institutes. The top development phase for Japanese Encephalitis is preclinical with ten drugs in that stage. The Japanese Encephalitis pipeline has eight drugs in development by companies and four by universities/ institutes. Some of the companies in the Japanese Encephalitis pipeline products market are: Ennaid Therapeutics, Theravectys and U.S. National Institutes of Health.
The key targets in the Japanese Encephalitis pipeline products market include Japanese Encephalitis Virus Envelope Protein E, Japanese Encephalitis Virus prM Protein, and Nonstructural Protein 5.
The key mechanisms of action in the Japanese Encephalitis pipeline product include Nonstructural Protein 5 Inhibitor with one drug in Discovery. The Japanese Encephalitis pipeline products include one routes of administration with the top ROA being Oral and nine key molecule types in the Japanese Encephalitis pipeline products market including Vaccine, and Inactivated Vaccine.
Japanese Encephalitis overview
Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness, and paralysis. Treatment targets the symptoms with pain relievers and anticonvulsants.
For a complete picture of Japanese Encephalitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
